lemborexant (Dayvigo)

From Aaushi
Jump to navigation Jump to search
[1][2]

Indications

Contraindications

Dosage

  • 5-10 mg

Tabs: 5 mg, 10 mg

Pharmacokinetics

Adverse effects

Mechanism of action

More general terms

References

  1. ↑ Remaly J FDA Approves Lemborexant (Dayvigo) for Insomnia. Medscape - Dec 23, 2019. https://www.medscape.com/viewarticle/923054
  2. ↑ 2.0 2.1 2.2 2.3 Talebraza S et al Geriatrics Evaluation & Management Tools American Geriatrics Society. 2021 https://geriatricscareonline.org/ProductAbstract/geriatrics-evaluation-management-tools/B007/

Database

Retrieved from "https://aaushi.info/w/index.php?title=A56080&oldid=1069261"